GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bayzed Health Group 2609.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

2.62

-2.96%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Bayzed Health Group

Its shares trade on HKEX under the ticker 2609.HK. It has been listed since 23 June 2025. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.12bn and a net loss of CN¥13.0m. At that date it held total assets of CN¥2.56bn and shareholders' equity of CN¥1.52bn.

Bayzed Health Group, Inc. engages in the provision of investment, medical, and healthcare services. The company is headquartered in Beijing, Beijing. The company went IPO on 2025-06-23. The firm provides services in the field of full-cycle medical services for tumors, including screening, diagnosis, treatment and rehabilitation. The firm is principally engaged in hospital business, hospital management services, supply of pharmaceuticals, medical equipment and consumables and other businesses. The firm's business also includes tumor diagnosis, tumor treatment, tumor rehabilitation and hospice care for patients, as well as early cancer screening, tumor vaccination and health management services for other potential healthy people. The firm mainly operates its businesses in China market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Providers & Services
Listed since
23 Jun 2025
Employees
2,112

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Beijing with 2,112 employees
  • Provides full-cycle medical services for tumors including screening, diagnosis, treatment, and rehabilitation
  • Operates in the health care sector with services in hospital business, management, pharmaceuticals, and medical equipment

Weaknesses

  • IPO scheduled for 2025-06-23, indicating limited historical market presence
  • Relies solely on the China market for business operations
  • No mention of international expansion or diversification strategies

Opportunities

  • Growth potential in China's health care sector
  • Expansion into tumor vaccination and health management services for healthy individuals
  • Potential for increased market share in full-cycle tumor services

Threats

  • Dependence on the China market may expose the company to regional economic fluctuations
  • IPO in 2025-06-23 may face market volatility during listing
  • Competition in the health care sector could impact service demand

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.